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CIK cells therapy has been evaluated as an adoptive cell immunotherapy for cancer patients, but there still have not
been any standardized systems for evaluating the antitumor efficacy yet. The WHO and RECIST criteria have already
been established for a few years but not sufficient to fully characterize the activity of immunotherapy. Based on
these two criteria, the irRC was proposed for evaluating the efficacy of immunotherapy. A variety of bioassays for
immune monitoring including the specific and non-specific methods, have been established. We recommend
detect levels of various immunocytes, immune molecules and soluble molecules to find the correlations among
them and clinicopathological characteristics to establish criteria for immunological classification. We also recommend a
paradigm shift for the oncologists in the evaluation of immune therapies to ensure assessment of activity based on
clinically relevant criteria and time points.
Keywords: CIK cells therapy, Tumor response, Evaluation systemMalignancy has become a major cause of human deaths
worldwide nowadays [1,2]. Unfortunately, traditional ther-
apies including surgery, chemotherapy and radiotherapy
often fail to eradicate tumor lesions completely and tend
to result in many adverse events [3]. Thus, novel approaches
for curing malignancies are urgently necessary.
In recent years, immunotherapy has emerged as an effi-
cacious treatment modality with encouraging efficacy and
slight adverse events in cancer therapy [4]. Among various
kinds of immunotherapy, cytokine-induced killer (CIK)
cells therapy has moved from the “bench to bedside” and
been suggested as a promising method [5].
CIK cells, a subset of T lymphocytes with a natural
killer T cell phenotype expressing both the CD3 and the
CD56 markers, present potent non-major histocompati-
bility complex-restricted cytotoxicity against a variety of
tumor target cells [6-15], which is similar to the NK cells
[15]. The serial biological events following CIK cells ad-
ministration to a cancer patient includes (a) immune* Correspondence: wcpjjt@163.com; jjtnew@163.com
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unless otherwise stated.activation and effective lymphocytes (mostly CD3+CD56+ T
lymphocytes) proliferation starting early after the first
administration, (b) clinically measurable antitumor effects
mediated by activated immune cells over weeks to months,
and (c) potential delayed effect on patient survival several
months or even longer after the first administration [16].
CIK cells therapy has been evaluated as an adoptive
cell immunotherapy for cancer patients in a number of
clinical trials [13,17-26]. In our department, CIK cells
therapy has been applied on more than 4000 cancer
patients since late 90' of last century, and recently we
have proposed a relatively standardized procedure CIK
cells therapy [27]. And we have discussed the role of
CIK cells infusion on immune enhancing [15]. But still,
during the practice we found that there still have not been
any standardized systems for evaluating the antitumor
efficacy yet, while the promising efficacy of CIK cells on
malignancies has been proved.
As widely acknowledged, the WHO and RECIST criteria
have already been established for years in order to evaluate
the efficacy of cytotoxic agents [28-31]. These criteria are
not sufficient to fully characterize the activity of immuno-
therapy since most long-term responses are observed after
an increase in tumor burden (TB) evaluated by WHO and
RECIST criteria [32]. Nevertheless, CIK cells are not ablehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ministration. More time is required for immunocytes ex-
pansion followed by infiltration of the tumor and a
subsequent measurable antitumor effect [16], which
means that radiographic evaluation of a progressive
disease (PD) evaluated by the WHO or RECIST criteria
does not necessarily mean therapeutic failure [33]. Fur-
thermore, durable stable disease (SD) might also suggests
that the appearance of measurable antitumor activity
could take longer time for immune therapies than for
cytotoxic therapies [34]. The facts reveal that the WHO or
RECIST criteria are not suitable for evaluating the antitu-
mor effect of CIK cells therapy.
Adjusting the clinical development paradigm from
traditional therapies to immunotherapy requires a proper
tool for evaluation, so the lack of standardized systems
becomes an obvious shortcoming of employing CIK cells
therapy. However, challenges are involved in each biological
event mentioned above since the antitumor response in-
duced by CIK cells therapy is not included in the traditional
evaluation system [34]. so it is urgently needed to establish
novel evaluation criteria for immune-related response.
Another reason is that there can be huge discrepancies of
the results of examinations for antitumor immunotherapy
under various conditions or in different laboratories. For
instance, it has been reported that a total of 36 laborator-
ies used enzyme linked immunospot assay (ELISPOT) to
examine the level of serum cytokine secreted by peripheral
blood mononuclear cell of the same patient and the re-
sults vary from negative to strong positive [16]. The lack
of a quality control measure for T cell–based assays that
can be applied as a gold standard has hampered the estab-
lishment of correlation between the antitumor effect of
immunotherapy including CIK cells therapy and clinical
outcomes.
Considering of these and based on WHO and RECIST,
a novel set of response criteria were evaluated in a few
large multinational studies on advanced melanoma re-
ceiving ipilimumab, a fully human monoclonal antibody
that blocks CTLA-4 [35,36]. In these studies, 4 distinct
response patterns were observed: immediate response
(response in baseline lesions-evident by week 12 with no
new lesions), durable SD, response after TB increase (re-
sponses after an initial increase in total TB), and response
in the presence of new lesions (a reduction in total TB
during or after the appearance of new lesions later than
week 12) [33]. Among these 4 response patterns, the
first two are conventional, while the latter two are novel
and specifically recognized by immunotherapeutic
agents. Particularly, the results of one case study of the
first novel tumor response pattern reveal that TB firstly
increases and then decreases to a complete response. Im-
portantly, all these 4 patterns seem to be associated with
promising survival outcome compared with patients withPD evaluated by WHO criteria [33]. In fact, it has been
found that PD (the appearance of new lesions or increase
in the size of existing lesions) might be resulted by just
lymphocytic infiltration but not the represent of true dis-
ease progression [37,38].
In order to create a process which systematically captures
all observed response patterns, the irRC, generally based
on the WHO and RECIST criteria but do not require a
substantial departure from standard oncology practice,
was proposed by Cancer Immunotherapy Consortium of
the Cancer Research Institute [33,39]. The irRC develops
a novelty in the measurement of new lesions that are
included in the total TB [40]. So generally, the irRC pro-
vides a means of accounting for delayed changes in TB
through confirmation of progression at subsequent time
points.
The overall response according to the irRC is derived
from time-point response assessments (based on total
TB) as irCR, complete disappearance of all lesions confirm-
ation by a repeat, consecutive assessment no less than
4 weeks from the date first recorded; irPR, decrease in TB ≥
50% relative to baseline confirmed by a consecutive assess-
ment at least 4 weeks after first record; irSD, not matching
the criteria for irCR or irPR, in absence of irPD; irPD, in-
crease in TB ≥ 25% relative to minimum recorded total
TB confirmation by a repeat, consecutive assessment no
less than 4 weeks from the date first recorded [33].
The irRC were defined based on data from ipilimumab
clinical trials, but their conceptual foundations result
from consistent observations with several agents across
the immune therapy community, and therefore it is
expected that these criteria will have broad applicability
to other immunotherapeutic agents. However, it is in-
appropriate to copy and apply the irRC mechanically for
the pattern of tumor response to CIK cells therapy in
malignant solid tumors, adjustment is required.
A variety of bioassays for immune monitoring, including
the specific and non-specific methods, has been estab-
lished. The specific and non-specific methods include
ELISPOT assay and cytometry-based tests such as
intracellular cytokine staining, HLA-peptide multimer
staining, and the carboxyfluorescein succinimidyl ester
assay [41-44], and delayed type hypersensitivity method is
applied to detect the existence of antibody-specific T
lymphocytes in vivo after treatment [45], and soluble-
MHC-petide tetramer methods are used for the amount
of T lymphocytes [42]. Non-specific immune responses
include flow cytometry determining peripheral blood
lymphocytes subtypes, and enzyme linked immunosorbent
assay or cytometric bead array methods determining the
serum level of some cytokines. Even though the funda-
mentals of these assays have been well established, a pleth-
ora of different laboratory protocols is used, which leads
to that results vary in a very wide spectrum [44]. However
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CIK cells administration in various cancers were similar in
different laboratories.
Though antitumor immunotherapy achieves the anti-
tumor effect by activating immune responses, it is still
not clear whether the clinical outcome is directly related
with the immune responses. Nijman et al. used ELISPOT
method to detect p53-specific T lymphocytes, and no rele-
vance between the therapeutic efficacy and T lymphocyte-
induced response was observed in this phase II clinical
trial on ovarian cancer [46]. But Weiner et al. applied the
combination regimen of peptide vaccine and GM-CSF
+/-IFN-α2b in the treatment of 120 cases of advanced ma-
lignant melanoma enrolled in a stage II clinical trial with
an average follow-up of 25.4 months, and found that those
who had a specific immune response enjoyed a signifi-
cantly longer overall survival time than those did not (21.3
vs. 13.4 months, P = 0.046), suggesting that the overall
survival time after the immunotherapy was related to
the immune response [47]. Additionally, the inability to
use cellular immune response assays to define biomarkers
and to investigate their correlation with clinical outcomes
has its roots in highly variable and often nonreproducible
assay results in multicenter trials [48,49]. Thus, adequate
indicators which reflect immune response could possibly
be biomarkers for evaluating the efficacy of CIK cells ther-
apy. But the challenge is to determine which biomarkers
have the greatest potential to be investigated as correlates
to clinical response. The ideal immunologic biomarkers
should be one which can (a) be measured easily from
bodily fluids, (b) is quantitative allowing for stratification
of patients based on magnitude of response and allowed
some qualitative assessment of the response, and (c) re-
flect the mechanism of action of the agent studied or the
direct effect of cancer immunity [50].
There are indicators in the published literature that
blood-based immunologic biomarkers that predict clinical
response can be developed [50]. We recommend detect
levels of various immunocytes, immune molecules and
soluble molecules, and find the correlations between them
and clinicopathological characteristics to establish stan-
dards for immunological classification. That is why we
perform CIK cells therapy and analyze the correlation
between the therapeutic efficacy and these levels to screen
out the immunocytes and proportions of immunocyte
subsets which directly affect the therapeutic efficacies.
Upon the clinical practice, we therefore recommend a
paradigm shift for the oncologist in the evaluation of im-
mune therapies to ensure assessment of activity based
on clinically relevant criteria and time points.
1. The overall survival and progression-free survival
time: the main parameters for evaluation
2. Regular assessment(1)CIK cells therapy response: evaluated by irRC
(2)Tumor markers (vary for different kinds of
malignancies)
(3)Patients’ status of quality of life (referring to
RECIST and WHO criteria)
3 Immune response monitoring
(1)Percentages and absolute values of T lymphocytes
including CD3+, CD4+, CD8+CD3+CD4+ and
CD3+CD8+ lymphocytes, Th1/Th17/Th2/Treg
cells, dendritic cells,
(2)Percentages and absolute values of CD3+ CD56+
lymphocytes (the )
(3)Toxicity of NK cells
(4)Granzymes and perforins of CD8+ T cells and
γδT cells
(5)Phenotypes of CD3+CD8+ T cells, CD3+CD4+ T
cells and γδT cells
(6)Detection of CD3+CD4+Foxp3+ T cells
(7)Activation marker including CD3+HLA- DR,
CD4+HLA- DR and CD8+HLA- DR
(8)Detection of antigen-specific T cells (CD4+ and
CD8+ T cells)
(9)CD4+ CD25+ Treg cells [51-53]
4 Soluble molecules levels monitoring
(1)Negative regulating cytokines: IL-4, IL-10, TGF-β
and VEGF.
(2)Positive regulating cytokines: IL-2, IL-12, IFN-γ
and TNF-α.
(3)T lymphocytes-regulating molecules including
B7-H4 [54], B7-H3, PD-L1 [55]
The indicators should be recruited anytime when
adequate novel ones are found, and need to be verified
in clinical trials enrolling large sample sizes.
Besides, the presence of CIK-related adverse events
has been shown to be predictive of better clinical re-
sponses and outcomes. On our experience, most pa-
tients receiving CIK cells therapy had an improvement
in their appetite, physical strength, sleeping, pain remis-
sion. There were rarely severe adverse events noted. All
moderate adverse events disappeared after allopathic
treatments. So the occurrence of adverse events cannot
be enrolled to measure the tumor response to CIK cells
therapy.
The final but the most point is that these items men-
tioned above can be scored separately, and added to-
gether then a scoring system is formed. The most
important point is to 1) to avoid the impact of prior
treatments on CIK cells therapy and 2) find the adequate
weight of each and every item.
Future perspective
Conclusively, the evaluation of therapeutic effect of CIK
cells therapy is based on the irRC but not restricted to
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various methods to improve the evaluation. But our rec-
ommendation is still far from perfection. Novel, adequate
methods should be verified in practice and more indica-
tors might be recruited. And a scoring system is required
but the score of each item should be verified. Progressive
clinical trials with large sample sizes should be performed
and provide the evidences for applying the criterion.
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